632 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34050611 | Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. | 2022 Feb | 2 |
2 | 34151456 | Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship. | 2022 Feb | 1 |
3 | 34473525 | Recent Advances in the Management of Metastatic Prostate Cancer. | 2022 Jan | 1 |
4 | 34629045 | Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair. | 2022 | 1 |
5 | 34670865 | GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. | 2022 Feb | 1 |
6 | 34732853 | Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. | 2022 Jan | 1 |
7 | 34812476 | Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review). | 2022 Jan | 2 |
8 | 34854226 | Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. | 2022 Apr | 1 |
9 | 34880123 | cAMP-Mediated Autophagy Promotes Cell Survival via ROS-Induced Activation of PARP1: Implications for Treatment of Acute Lymphoblastic Leukemia. | 2022 Mar 1 | 1 |
10 | 34954029 | FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | 2022 Jan | 1 |
11 | 34969765 | Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells. | 2022 Jan | 4 |
12 | 35000525 | Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. | 2022 Dec 31 | 2 |
13 | 35091172 | Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. | 2022 Feb 15 | 1 |
14 | 35097256 | Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide. | 2022 Jan 25 | 1 |
15 | 35130631 | PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin | 2022 Jan 25 | 3 |
16 | 35156571 | Durable Disease-Free Survival in a Patient with Metastatic Triple-Negative Breast Cancer Treated With Olaparib Monotherapy. | 2022 Feb 14 | 2 |
17 | 35159068 | Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? | 2022 Feb 4 | 1 |
18 | 35163037 | Sesquiterpene Lactones Potentiate Olaparib-Induced DNA Damage in p53 Wildtype Cancer Cells. | 2022 Jan 20 | 2 |
19 | 35163134 | THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. | 2022 Jan 21 | 1 |
20 | 35165509 | Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis. | 2022 | 2 |
21 | 35188042 | Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. | 2022 Feb 20 | 2 |
22 | 35191009 | Genetic medicine is accelerating in Japan. | 2022 Feb 21 | 1 |
23 | 35194903 | XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. | 2022 May | 4 |
24 | 35205643 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | 2022 Feb 11 | 2 |
25 | 35267438 | DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy. | 2022 Feb 23 | 1 |
26 | 35269669 | Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo. | 2022 Feb 25 | 2 |
27 | 35324529 | Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. | 2022 Mar 23 | 2 |
28 | 35343196 | A review on mechanisms of resistance to PARP inhibitors. | 2022 Mar | 1 |
29 | 35400012 | Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib. | 2022 Jan-Feb | 3 |
30 | 35408930 | Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells. | 2022 Mar 25 | 1 |
31 | 35419627 | An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. | 2022 May | 2 |
32 | 35444023 | Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. | 2022 Apr 20 | 1 |
33 | 35466317 | Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. | 2022 | 2 |
34 | 35480123 | Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation. | 2022 | 1 |
35 | 35486574 | Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. | 2022 | 3 |
36 | 35494030 | Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review. | 2022 | 2 |
37 | 35517402 | Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. | 2022 | 2 |
38 | 35545049 | The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. | 2022 May 10 | 2 |
39 | 35593736 | First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. | 2022 May 20 | 1 |
40 | 35611209 | Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. | 2022 Apr 16 | 3 |
41 | 35619904 | OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. | 2022 | 1 |
42 | 35624090 | FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2'-deoxycytidine and 5-hydroxymethyl-2'-deoxyuridine. | 2022 May 27 | 2 |
43 | 35628590 | Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. | 2022 May 21 | 1 |
44 | 35636395 | Parp Inhibition and Beyond in Brca- Associated Breast Cancer in Women: A State- Of- The- Art Summary of (Pre) - Clinical Research into Risk Reduction and Clinical Benefits. | 2022 May 30 | 1 |
45 | 32079692 | Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. | 2021 Jan 1 | 1 |
46 | 32164505 | A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. | 2021 | 1 |
47 | 32409690 | TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. | 2021 Feb | 1 |
48 | 32790034 | PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. | 2021 Jan | 2 |
49 | 32814472 | Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer. | 2021 Jun | 1 |
50 | 33069804 | Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. | 2021 Feb 15 | 4 |